Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
16 avr. 2013 11h55 HE
|
Synergy Pharmaceuticals
NEW YORK, April 16, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its...
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock
10 avr. 2013 20h53 HE
|
Synergy Pharmaceuticals
NEW YORK, April 10, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing of an...
Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock
09 avr. 2013 16h34 HE
|
Synergy Pharmaceuticals
NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is offering...
Synergy Pharmaceuticals Reports 2012 Fourth Quarter and Full-Year Financial Results
18 mars 2013 17h00 HE
|
Synergy Pharmaceuticals
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results...
Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013
15 mars 2013 05h00 HE
|
Synergy Pharmaceuticals
NEW YORK, March 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that study results...
Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences
22 févr. 2013 06h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President...
Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
11 févr. 2013 05h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its common stock...
Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences
07 févr. 2013 08h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President...
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
28 janv. 2013 05h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today that oral dosing of healthy...
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
17 janv. 2013 16h05 HE
|
Synergy Pharmaceuticals
NEW YORK, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its previously...